N3538

Nateglinid

≥98% (HPLC), solid

• Synonym(e): N-[(trans-4-Isopropylcyclohexyl)-carbonyl]-D-phenylalanin, Fastic, Starlix, Starsis
• Empirische Formel (Hill-System): C₁₉H₂₇NO₃
• CAS-Nummer: 105816-04-4
• Molekulargewicht: 317.42
• MDL-Nummer: MFCD00875706
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329818636
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: solid
• Farbe: white to off-white
• Löslichkeit: DMSO: >5 mg/mL; H₂O: insoluble
• Ersteller: Novartis
• Lagertemp.: room temp
• SMILES String: CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O
• InChI: 1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
• InChIKey: OELFLUMRDSZNSF-BRWVUGGUSA-N
• Angaben zum Gen: human ... ABCC8(6833) , KCNJ11(3767)

Beschreibung

Biochem./physiol. Wirkung

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.

Leistungsmerkmale und Vorteile

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)